MFG Wealth Management Inc. Increases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

MFG Wealth Management Inc. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 34.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,226 shares of the medical device company's stock after buying an additional 6,987 shares during the quarter. DexCom accounts for 1.8% of MFG Wealth Management Inc.'s portfolio, making the stock its 27th biggest holding. MFG Wealth Management Inc.'s holdings in DexCom were worth $1,859,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in DXCM. Private Trust Co. NA grew its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after buying an additional 245 shares in the last quarter. Golden State Wealth Management LLC grew its position in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares in the last quarter. Optiver Holding B.V. acquired a new stake in DexCom during the fourth quarter worth about $33,000. TD Private Client Wealth LLC grew its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares in the last quarter. Finally, Larson Financial Group LLC lifted its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

DXCM stock traded up $1.29 during mid-day trading on Friday, hitting $86.33. The company had a trading volume of 4,632,374 shares, compared to its average volume of 4,393,450. The firm has a market cap of $33.85 billion, a PE ratio of 64.43, a price-to-earnings-growth ratio of 1.81 and a beta of 1.46. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19. The stock's fifty day moving average price is $81.34 and its two-hundred day moving average price is $79.54.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business's revenue was up 12.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.32 EPS. On average, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the transaction, the director now owns 56,621 shares of the company's stock, valued at $4,706,903.73. The trade was a 4.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the sale, the executive vice president now directly owns 109,621 shares of the company's stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,724 shares of company stock valued at $2,157,034 over the last quarter. Company insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on DXCM. The Goldman Sachs Group began coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price target for the company. Piper Sandler cut their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Citigroup restated a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Robert W. Baird cut their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research note on Saturday, June 21st. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.